ImmuCell

ImmuCell Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of ImmuCell (ICCC) as of Oct 20, 2026 is 190.86. In the previous year, Cash Conversion Cycle (CCC) was 173.33 — a change of 10.12% (higher).

Cash Conversion Cycle

190.86

YoY

10.12%

Last updated:

Cash Conversion Cycle (CCC) of ImmuCell is 2025 190.86 . Cash Conversion Cycle (CCC) of ImmuCell was 2024 173.33 . It decreases by 10.12% higher compared to the previous year.

The ImmuCell Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
139.79 USD
Jan 1, 2019
145.34 USD
Jan 1, 2020
106.97 USD
Jan 1, 2021
131.87 USD
Jan 1, 2022
210.05 USD
Jan 1, 2023
238.94 USD
Jan 1, 2024
173.33 USD
Jan 1, 2025
190.86 USD
The ImmuCell Cash Conversion Cycle history
YEARCash Conversion CycleYoY
190.86+10.12%
173.33-27.46%
238.94+13.76%
210.05+59.28%
131.87+23.27%
106.97-26.40%
145.34+3.97%
139.79+33.27%
104.89+13.13%
92.71+6.40%
87.13-17.25%
105.29—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Cash Conversion Cycle (CCC) of ImmuCell is 190.86 in 2025.

Cash Conversion Cycle (CCC) of ImmuCell changed from 173.33 to 190.86, representing a 10.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) ImmuCell since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s ImmuCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ImmuCell

All Key Metrics — ImmuCell